{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T12:07:44Z","timestamp":1784290064021,"version":"3.55.0"},"reference-count":55,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/501100024491","name":"institut universitaire sur les d\u00e9pendances","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000156","name":"Fonds de Recherche du Qu\u00e9bec - Sant\u00e9","doi-asserted-by":"publisher","award":["10.69777\/363969"],"award-info":[{"award-number":["10.69777\/363969"]}],"id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013392","name":"Minist\u00e8re de la Sant\u00e9 et des Services sociaux","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013392","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Psychopharmacol"],"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Cannabidiol (CBD) is widely consumed in low-dose products. However, evidence for its psychotropic effects at non-clinical doses is sparse and inconsistent.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aims:<\/jats:title>\n                    <jats:p>To characterise the acute behavioural effects of low-dose synthetic CBD in healthy volunteers. We hypothesised that 200\u2009mg of CBD would produce a greater peak pleasant drug effect than a placebo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>In a triple-blind, randomised, crossover trial at the CHUM research centre, Montreal, Canada, 70 healthy occasional cannabis users received single oral doses of 20, 50, 100 and 200\u2009mg synthetic CBD and placebo immediately after a high-fat meal. The primary outcome, a participant-rated visual analogue scale of pleasant drug effect (0\u2013100), was assessed at five timepoints post-dosing during each visit. Other measurements included additional participant ratings of drug effects, as well as positive and negative affect, dissociation, anxiety, blood pressure, heart rate, and respiratory rate.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Two hundred milligrams of synthetic CBD dose produced an average 12.8% [95% CI\u2009=\u20093.8% to 21.8%] higher peak pleasant drug effect score compared to placebo (Cohen\u2019s\n                      <jats:italic toggle=\"yes\">d<\/jats:italic>\n                      \u2009=\u20090.479 [0.089 to 0.869],\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      <jats:sub>corr<\/jats:sub>\n                      \u2009=\u20090.044). No other dose of CBD showed a significant effect for the primary outcome versus placebo. All adverse events were mild or moderate in severity.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>The highest dose of CBD tested produced a slight but perceptible pleasurable subjective drug effect. This effect may differ based on prandial state and in clinical populations and populations with heavier cannabis use. Single doses of 100\u2009mg synthetic CBD or less are unlikely to produce any discernible psychoactive effect in healthy, occasional users.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial registration:<\/jats:title>\n                    <jats:p>The study was registered on ClinicalTrials.gov (NCT05407285).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/02698811261464527","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T09:31:55Z","timestamp":1784107915000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Acute behavioural effects of low-dose cannabidiol: A randomised crossover trial in healthy volunteers"],"prefix":"10.1177","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7813-0281","authenticated-orcid":false,"given":"Lucy A.","family":"Chester","sequence":"first","affiliation":[{"name":"Research Centre, Centre Hospitalier de l\u2019Universit\u00e9 de Montr\u00e9al, QC, Canada"},{"name":"Department of Psychiatry and Addiction, Faculty of Medicine, Universit\u00e9 de Montr\u00e9al, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8111-0484","authenticated-orcid":false,"given":"Fran\u00e7ois-Olivier","family":"Hebert","sequence":"additional","affiliation":[{"name":"Research Centre, Centre Hospitalier de l\u2019Universit\u00e9 de Montr\u00e9al, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Lachance-Touchette","sequence":"additional","affiliation":[{"name":"Research Centre, Centre Hospitalier de l\u2019Universit\u00e9 de Montr\u00e9al, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2069-4552","authenticated-orcid":false,"given":"Amani","family":"Mahroug","sequence":"additional","affiliation":[{"name":"Research Centre, Centre Hospitalier de l\u2019Universit\u00e9 de Montr\u00e9al, QC, Canada"},{"name":"Department of Psychiatry and Addiction, Faculty of Medicine, Universit\u00e9 de Montr\u00e9al, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9356-9233","authenticated-orcid":false,"given":"Anita","family":"Abboud","sequence":"additional","affiliation":[{"name":"Research Centre, Centre Hospitalier de l\u2019Universit\u00e9 de Montr\u00e9al, QC, Canada"},{"name":"Department of Psychiatry and Addiction, Faculty of Medicine, Universit\u00e9 de Montr\u00e9al, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0324-3564","authenticated-orcid":false,"given":"Tess Pelletier","family":"McCrea","sequence":"additional","affiliation":[{"name":"Research Centre, Centre Hospitalier de l\u2019Universit\u00e9 de Montr\u00e9al, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9239-1146","authenticated-orcid":false,"given":"Samer","family":"Mansour","sequence":"additional","affiliation":[{"name":"Research Centre, Centre Hospitalier de l\u2019Universit\u00e9 de Montr\u00e9al, QC, Canada"},{"name":"Department of Cardiology, Faculty of Medicine, Universit\u00e9 de Montr\u00e9al, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9737-6818","authenticated-orcid":false,"given":"St\u00e9phanie","family":"Marsan","sequence":"additional","affiliation":[{"name":"Research Centre, Centre Hospitalier de l\u2019Universit\u00e9 de Montr\u00e9al, QC, Canada"},{"name":"Department of Family and Emergency Medicine, Faculty of Medicine, Universit\u00e9 de Montr\u00e9al, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8474-508X","authenticated-orcid":false,"given":"Didier","family":"Jutras-Aswad","sequence":"additional","affiliation":[{"name":"Research Centre, Centre Hospitalier de l\u2019Universit\u00e9 de Montr\u00e9al, QC, Canada"},{"name":"Department of Psychiatry and Addiction, Faculty of Medicine, Universit\u00e9 de Montr\u00e9al, QC, Canada"},{"name":"Institut universitaire sur les d\u00e9pendances, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"key":"e_1_3_3_2_1","doi-asserted-by":"crossref","unstructured":"Arndt DL de Wit H (2017) Cannabidiol does not dampen responses to emotional stimuli in healthy adults. Cannabis and Cannabinoid Research 2: 105\u2013113. https:\/\/doi.org\/10.1089\/can.2017.0014","DOI":"10.1089\/can.2017.0014"},{"key":"e_1_3_3_3_1","doi-asserted-by":"crossref","unstructured":"Arnold JC McCartney D Suraev A et al. (2023) The safety and efficacy of low oral doses of cannabidiol: An evaluation of the evidence. Clinical and Translational Science 16(1): 10\u201330. https:\/\/doi.org\/10.1111\/cts.13425","DOI":"10.1111\/cts.13425"},{"key":"e_1_3_3_4_1","doi-asserted-by":"crossref","unstructured":"Babalonis S Haney M Malcolm RJ et al. (2017) Oral cannabidiol does not produce a signal for abuse liability in frequent marijuana smokers. Drug and Alcohol Dependence 172: 9\u201313. https:\/\/doi.org\/10.1016\/j.drugalcdep.2016.11.030","DOI":"10.1016\/j.drugalcdep.2016.11.030"},{"key":"e_1_3_3_5_1","doi-asserted-by":"crossref","unstructured":"Bang H Ni L Davis CE (2004) Assessment of blinding in clinical trials. Controlled Clinical Trials 25(2): 143\u2013156. https:\/\/doi.org\/10.1016\/j.cct.2003.10.016","DOI":"10.1016\/j.cct.2003.10.016"},{"key":"e_1_3_3_6_1","doi-asserted-by":"crossref","unstructured":"Barkus EJ Stirling J Hopkins RS et al. (2006) Cannabis-induced psychosis-like experiences are associated with high schizotypy. Psychopathology 39: 175\u2013178. https:\/\/doi.org\/10.1159\/000092678","DOI":"10.1159\/000092678"},{"key":"e_1_3_3_7_1","doi-asserted-by":"crossref","unstructured":"Bates D M\u00e4chler M Bolker BM et al. (2015) Fitting linear mixed-effects models using lme4. Journal of Statistical Software 67: 1\u201348. https:\/\/doi.org\/10.18637\/jss.v067.i01","DOI":"10.18637\/jss.v067.i01"},{"key":"e_1_3_3_8_1","doi-asserted-by":"crossref","unstructured":"Bergamaschi MM Queiroz RHC Chagas MHN et al. (2011) Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-na\u00efve social phobia patients. Neuropsychopharmacology 36: 1219\u20131226. https:\/\/doi.org\/10.1038\/npp.2011.6","DOI":"10.1038\/npp.2011.6"},{"key":"e_1_3_3_9_1","doi-asserted-by":"crossref","unstructured":"Bonn-Miller MO Loflin MJE Thomas BF et al. (2017) Labeling accuracy of cannabidiol extracts sold online. Journal of the American Medical Association 318: 1708\u20131709. https:\/\/doi.org\/10.1001\/jama.2017.11909","DOI":"10.1001\/jama.2017.11909"},{"key":"e_1_3_3_10_1","doi-asserted-by":"crossref","unstructured":"Borgwardt SJ Allen P Bhattacharyya S et al. (2008) Neural basis of Delta-9-tetrahydrocannabinol and cannabidiol: Effects during response inhibition. Biological Psychiatry 64(11): 966\u2013973. https:\/\/doi.org\/10.1016\/j.biopsych.2008.05.011","DOI":"10.1016\/j.biopsych.2008.05.011"},{"key":"e_1_3_3_11_1","doi-asserted-by":"crossref","unstructured":"Bremner JD Krystal JH Putnam FW et al. (1998) Measurement of dissociative states with the clinician-administered dissociative states scale (CADSS). Journal of Traumatic Stress 11: 125\u2013136. https:\/\/doi.org\/10.1023\/A:1024465317902","DOI":"10.1023\/A:1024465317902"},{"key":"e_1_3_3_12_1","doi-asserted-by":"crossref","unstructured":"Britch SC Babalonis S Walsh SL (2021) Cannabidiol: Pharmacology and therapeutic targets. Psychopharmacology 238(1): 9\u201328. https:\/\/doi.org\/10.1007\/s00213-020-05712-8","DOI":"10.1007\/s00213-020-05712-8"},{"key":"e_1_3_3_13_1","doi-asserted-by":"crossref","unstructured":"Brooks ME Kristensen K Benthem KJv et al. (2017) GlmmTMB balances speed and flexibility among packages for zero-inflated generalized linear mixed modeling. The R Journal 9(2): 378\u2013400. https:\/\/doi.org\/10.32614\/RJ-2017-066","DOI":"10.32614\/RJ-2017-066"},{"key":"e_1_3_3_14_1","unstructured":"Burns M Moskowitz H (1977) Psychophysical tests for DWI arrest. HS-802-424;SCRI-TR-77-2;NTIS-PB269309. United States Department of Transportation. https:\/\/doi.org\/10.21949\/1524965"},{"key":"e_1_3_3_15_1","doi-asserted-by":"crossref","unstructured":"Chesney E McGuire P Freeman TP et al. (2020) Lack of evidence for the effectiveness or safety of over-the-counter cannabidiol products. Therapeutic Advances in Psychopharmacology 10: 045125320954992. https:\/\/doi.org\/10.1177\/2045125320954992","DOI":"10.1177\/2045125320954992"},{"key":"e_1_3_3_16_1","doi-asserted-by":"crossref","unstructured":"Coelho CdF Vieira RP Ara\u00fajo-Junior OS et al. (2024) The impact of cannabidiol treatment on anxiety disorders: A systematic review of randomized controlled clinical trials. Life 14(11): 1373. https:\/\/doi.org\/10.3390\/life14111373","DOI":"10.3390\/life14111373"},{"key":"e_1_3_3_17_1","doi-asserted-by":"crossref","unstructured":"Crockett J Critchley D Tayo B et al. (2020) A phase 1 randomized pharmacokinetic trial of the effect of different meal compositions whole milk and alcohol on cannabidiol exposure and safety in healthy subjects. Epilepsia 61(2): 267\u2013277. https:\/\/doi.org\/10.1111\/epi.16419","DOI":"10.1111\/epi.16419"},{"key":"e_1_3_3_18_1","doi-asserted-by":"crossref","unstructured":"Englund A Oliver D Chesney E et al. (2023) Does cannabidiol make cannabis safer? A randomised double-blind cross-over trial of cannabis with four different CBD:THC ratios. Neuropsychopharmacology 48(6): 869\u2013876. https:\/\/doi.org\/10.1038\/s41386-022-01478-z","DOI":"10.1038\/s41386-022-01478-z"},{"key":"e_1_3_3_19_1","doi-asserted-by":"crossref","unstructured":"Finlay DB Sircombe KJ Nimick M et al. (2020) Terpenoids from cannabis do not mediate an entourage effect by acting at Cannabinoid receptors. Frontiers in Pharmacology 11: 359. https:\/\/doi.org\/10.3389\/fphar.2020.00359","DOI":"10.3389\/fphar.2020.00359"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2021.103381"},{"key":"e_1_3_3_21_1","unstructured":"Food Standards Agency (2025) Cannabidiol (CBD) guidance for England and Wales. Available at: https:\/\/www.food.gov.uk\/business-guidance\/cannabidiol-cbd (accessed 2 July 2025)."},{"key":"e_1_3_3_22_1","doi-asserted-by":"crossref","unstructured":"Gallily R Yekhtin Z Hanu\u0161 L (2015) Overcoming the bell-shaped dose-response of cannabidiol by using Cannabis extract enriched in cannabidiol. Pharmacology & Pharmacy 6: 75\u201385. https:\/\/doi.org\/10.4236\/pp.2015.62010","DOI":"10.4236\/pp.2015.62010"},{"key":"e_1_3_3_23_1","doi-asserted-by":"crossref","unstructured":"Ghabrash MF Coronado-Montoya S Aoun J et al. (2020) Cannabidiol for the treatment of psychosis among patients with schizophrenia and other primary psychotic disorders: A systematic review with a risk of bias assessment. Psychiatry Research 286: 112890. https:\/\/doi.org\/10.1016\/j.psychres.2020.112890","DOI":"10.1016\/j.psychres.2020.112890"},{"key":"e_1_3_3_24_1","doi-asserted-by":"crossref","unstructured":"Harris HM Rousseau MA Wanas AS et al. (2019) Role of Cannabinoids and terpenes in Cannabis-mediated analgesia in rats. Cannabis & Cannabinoid Research 4(3): 177\u2013182. https:\/\/doi.org\/10.1089\/can.2018.0054","DOI":"10.1089\/can.2018.0054"},{"key":"e_1_3_3_25_1","doi-asserted-by":"crossref","unstructured":"Hatav A Vysotski Y Shapira A et al. (2025) Machine-learning of medical cannabis chemical profiles reveals analgesia beyond placebo expectations. Communications Medicine 5(1): 295. https:\/\/doi.org\/10.1038\/s43856-025-00996-3","DOI":"10.1038\/s43856-025-00996-3"},{"key":"e_1_3_3_26_1","doi-asserted-by":"crossref","unstructured":"Hjorth\u00f8j CR Fohlmann A Larsen AM et al. (2012) Correlations and agreement between delta-9-tetrahydrocannabinol (THC) in blood plasma and timeline follow-back (TLFB)-assisted self-reported use of cannabis of patients with cannabis use disorder and psychotic illness attending the CapOpus randomized clin. Addiction 107: 1123\u20131131. https:\/\/doi.org\/10.1111\/j.1360-0443.2011.03757.x","DOI":"10.1111\/j.1360-0443.2011.03757.x"},{"key":"e_1_3_3_27_1","doi-asserted-by":"crossref","unstructured":"Hundal H Lister R Evans N et al. (2018) The effects of cannabidiol on persecutory ideation and anxiety in a high trait paranoid group. Journal of Psychopharmacology 32: 276\u2013282. https:\/\/doi.org\/10.1177\/0269881117737400","DOI":"10.1177\/0269881117737400"},{"key":"e_1_3_3_28_1","doi-asserted-by":"crossref","unstructured":"Jacobson MR Watts JJ Boileau I et al. (2019) A systematic review of phytocannabinoid exposure on the endocannabinoid system: Implications for psychosis. European Neuropsychopharmacology 29: 330\u2013348. https:\/\/doi.org\/10.1016\/j.euroneuro.2018.12.014","DOI":"10.1016\/j.euroneuro.2018.12.014"},{"key":"e_1_3_3_29_1","doi-asserted-by":"crossref","unstructured":"Koltai H Namdar D (2020) Cannabis phytomolecule \u2018entourage\u2019: From domestication to medical use. Trends in Plant Science 25(10): 976\u2013984 https:\/\/doi.org\/10.1016\/j.tplants.2020.04.007","DOI":"10.1016\/j.tplants.2020.04.007"},{"key":"e_1_3_3_30_1","volume-title":"emmeans: Estimated Marginal Means, aka Least-Squares Means","author":"Lenth RV","year":"2023","unstructured":"Lenth RV (2023) emmeans: Estimated Marginal Means, aka Least-Squares Means. R package version 1.6.3 ed. Comprehensive R Archive Network (CRAN)."},{"key":"e_1_3_3_31_1","doi-asserted-by":"crossref","unstructured":"Leweke FM (2012) Anandamide dysfunction in prodromal and established psychosis. Current Pharmaceutical Design 18(32): 5188\u20135193. https:\/\/doi.org\/10.2174\/138161212802884843","DOI":"10.2174\/138161212802884843"},{"key":"e_1_3_3_32_1","doi-asserted-by":"crossref","unstructured":"Leweke FM Piomelli D Pahlisch F et al. (2012) Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Translational Psychiatry 2: e94. https:\/\/doi.org\/10.1038\/tp.2012.15","DOI":"10.1038\/tp.2012.15"},{"key":"e_1_3_3_33_1","author":"Lumivero","year":"2023","unstructured":"Lumivero (2023) NVivo, 14 edn. Lumivero.","journal-title":"NVivo"},{"key":"e_1_3_3_34_1","doi-asserted-by":"crossref","unstructured":"Lutz B Marsicano G Maldonado R et al. (2015) The endocannabinoid system in guarding against fear anxiety and stress. Nature Reviews Neurosciences 16(12): 705\u2013718. https:\/\/doi.org\/10.1038\/nrn4036","DOI":"10.1038\/nrn4036"},{"key":"e_1_3_3_35_1","doi-asserted-by":"crossref","unstructured":"Martinotti G Di Forti M (2025) Cannabis use and psychosis: Evidence and new clinical features of a new epidemic. European Neuropsychopharmacology 91: 45\u201346. https:\/\/doi.org\/10.1016\/j.euroneuro.2024.11.007","DOI":"10.1016\/j.euroneuro.2024.11.007"},{"key":"e_1_3_3_36_1","doi-asserted-by":"crossref","unstructured":"Moltke J Hindocha C (2021) Reasons for cannabidiol use: A cross-sectional study of CBD users focusing on self-perceived stress anxiety and sleep problems. Journal of Cannabis Research 3(1): 5. https:\/\/doi.org\/10.1186\/s42238-021-00061-5","DOI":"10.1186\/s42238-021-00061-5"},{"key":"e_1_3_3_37_1","doi-asserted-by":"crossref","unstructured":"Morean ME de Wit H King AC et al. (2013) The drug effects questionnaire: Psychometric support across three drug types. Psychopharmacology 227(1): 177\u2013192. https:\/\/doi.org\/10.1007\/s00213-012-2954-z","DOI":"10.1007\/s00213-012-2954-z"},{"key":"e_1_3_3_38_1","doi-asserted-by":"crossref","unstructured":"Pintori N Caria F De Luca MA et al. (2023) THC and CBD: Villain versus hero? Insights into adolescent exposure. International Journal of Molecular Sciences 24: 5251. https:\/\/doi.org\/10.3390\/ijms24065251","DOI":"10.3390\/ijms24065251"},{"key":"e_1_3_3_39_1","doi-asserted-by":"crossref","unstructured":"Procaccia S Lewitus GM Lipson Feder C et al. (2022) Cannabis for medical use: Versatile plant rather than a single drug. Frontiers in Pharmacology 13: 894960. https:\/\/doi.org\/10.3389\/fphar.2022.894960","DOI":"10.3389\/fphar.2022.894960"},{"key":"e_1_3_3_40_1","volume-title":"Canada\u2019s Lower-Risk Cannabis Use Guidelines (LRCUG)","author":"Public Health Agency of Canada","year":"2019","unstructured":"Public Health Agency of Canada (2019) Canada\u2019s Lower-Risk Cannabis Use Guidelines (LRCUG). Public Health Agency of Canada."},{"key":"e_1_3_3_41_1","volume-title":"R: A Language and Environment for Statistical Computing","author":"R Core Team","year":"2024","unstructured":"R Core Team (2024) R: A Language and Environment for Statistical Computing, 4.4.1th edn. R Foundation for Statistical Computing."},{"key":"e_1_3_3_42_1","doi-asserted-by":"crossref","unstructured":"Raz N Eyal AM Zeitouni DB et al. (2023) Selected cannabis terpenes synergize with THC to produce increased CB1 receptor activation. Biochemical Pharmacology 212: 115548. https:\/\/doi.org\/10.1016\/j.bcp.2023.115548","DOI":"10.1016\/j.bcp.2023.115548"},{"key":"e_1_3_3_43_1","doi-asserted-by":"crossref","unstructured":"Rudisill TM Innes KK Wen S et al. (2023) The effects of cannabidiol on subjective states cognition and psychomotor function in healthy adults: A randomized clinical trial. Fundamental & Clinical Pharmacology 37(3): 663\u2013672. https:\/\/doi.org\/10.1111\/fcp.12868","DOI":"10.1111\/fcp.12868"},{"key":"e_1_3_3_44_1","doi-asserted-by":"crossref","unstructured":"Sainz-Cort A Jimenez-Garrido D Munoz-Marron E et al. (2021) Opposite roles for cannabidiol and delta-9-tetrahydrocannabinol in psychotomimetic effects of Cannabis extracts: A naturalistic controlled study. Journal of Clinical Psychopharmacology 41(5): 561\u2013570. https:\/\/doi.org\/10.1097\/JCP.0000000000001457","DOI":"10.1097\/JCP.0000000000001457"},{"key":"e_1_3_3_45_1","doi-asserted-by":"crossref","unstructured":"Santiago M Sachdev S Arnold JC et al. (2019) Absence of entourage: Terpenoids commonly found in Cannabis sativa do not modulate the functional activity of \u03949-THC at human CB1 and CB2 receptors. Cannabis & Cannabinoid Research 4(3): 165\u2013176. https:\/\/doi.org\/10.1089\/can.2019.0016","DOI":"10.1089\/can.2019.0016"},{"key":"e_1_3_3_46_1","doi-asserted-by":"crossref","unstructured":"Schoedel KA Szeto I Setnik B et al. (2018) Abuse potential assessment of cannabidiol (CBD) in recreational polydrug users: A randomized double-blind controlled trial. Epilepsy & Behavior 88: 162\u2013171. https:\/\/doi.org\/10.1016\/j.yebeh.2018.07.027","DOI":"10.1016\/j.yebeh.2018.07.027"},{"key":"e_1_3_3_47_1","doi-asserted-by":"crossref","unstructured":"Simei JLQ Souza JDR Lisboa JR et al. (2024) Does the \u201centourage effect\u201d in Cannabinoids exist? A narrative scoping review. Cannabis & Cannabinoid Research 9(5): 1202\u20131216. https:\/\/doi.org\/10.1089\/can.2023.0052","DOI":"10.1089\/can.2023.0052"},{"key":"e_1_3_3_48_1","doi-asserted-by":"crossref","unstructured":"Solowij N Broyd SJ Greenwood L-m et al. (2019) A randomised controlled trial of vaporised \u03949-tetrahydrocannabinol and cannabidiol alone and in combination in frequent and infrequent cannabis users: Acute intoxication effects. European Archives of Psychiatry and Clinical Neuroscience 269: 17\u201335. https:\/\/doi.org\/10.1007\/s00406-019-00978-2","DOI":"10.1007\/s00406-019-00978-2"},{"key":"e_1_3_3_49_1","doi-asserted-by":"publisher","DOI":"10.1002\/9780470479216.corpsy0943"},{"key":"e_1_3_3_50_1","doi-asserted-by":"crossref","unstructured":"Spindle TR Cone EJ Goffi E et al. (2020) Pharmacodynamic effects of vaporized and oral cannabidiol (CBD) and vaporized CBD-dominant cannabis in infrequent cannabis users. Drug and Alcohol Dependence 211: 107937. https:\/\/doi.org\/10.1016\/j.drugalcdep.2020.107937","DOI":"10.1016\/j.drugalcdep.2020.107937"},{"key":"e_1_3_3_51_1","doi-asserted-by":"crossref","unstructured":"Taylor L Crockett J Tayo B et al. (2020) Abrupt withdrawal of cannabidiol (CBD): A randomized trial. Epilepsy & Behavior 104: 106938. https:\/\/doi.org\/10.1016\/j.yebeh.2020.106938","DOI":"10.1016\/j.yebeh.2020.106938"},{"key":"e_1_3_3_52_1","volume-title":"Safety of Low Dose Cannabidiol","author":"Therapeutic Goods Administration","year":"2020","unstructured":"Therapeutic Goods Administration (2020) Safety of Low Dose Cannabidiol. ACT."},{"key":"e_1_3_3_53_1","doi-asserted-by":"crossref","unstructured":"van Buuren S Groothuis-Oudshoorn K (2011) Mice: Multivariate imputation by chained equations in R. Journal of Statistical Software 45: 1\u201367. https:\/\/doi.org\/10.18637\/jss.v045.i03","DOI":"10.18637\/jss.v045.i03"},{"key":"e_1_3_3_54_1","doi-asserted-by":"crossref","unstructured":"Watson D Clark LA Tellegan A (1988) Development and validation of brief measures of positive and negative affect: The PANAS scales. Journal of Personality and Social Psychology 54(6): 1063\u20131070. https:\/\/doi.org\/10.1037\/0022-3514.54.6.1063","DOI":"10.1037\/0022-3514.54.6.1063"},{"key":"e_1_3_3_55_1","doi-asserted-by":"crossref","unstructured":"White AG LeCates J Birnbaum HG et al. (2015) Positive subjective measures in abuse liability studies and real-world nonmedical use: Potential impact of abuse-deterrent opioids on rates of nonmedical use and associated healthcare costs. Journal of Opioid Management 11(3): 199-10 https:\/\/doi.org\/10.5055\/jom.2015.0269","DOI":"10.5055\/jom.2015.0269"},{"key":"e_1_3_3_56_1","doi-asserted-by":"crossref","unstructured":"Woelfl T Rohleder C Mueller JK et al. (2020) Effects of cannabidiol and delta-9-tetrahydrocannabinol on emotion cognition and attention: A double-blind placebo-controlled randomized experimental trial in healthy volunteers. Frontiers in Psychiatry 11: 576877. https:\/\/doi.org\/10.3389\/fpsyt.2020.576877","DOI":"10.3389\/fpsyt.2020.576877"}],"container-title":["Journal of Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811261464527","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/02698811261464527","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811261464527","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T11:48:12Z","timestamp":1784288892000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/02698811261464527"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":55,"alternative-id":["10.1177\/02698811261464527"],"URL":"https:\/\/doi.org\/10.1177\/02698811261464527","relation":{},"ISSN":["0269-8811","1461-7285"],"issn-type":[{"value":"0269-8811","type":"print"},{"value":"1461-7285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]},"article-number":"02698811261464527"}}